Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

NCT06026332 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT06026332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06026332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Terminated
Start date
September 15, 2023
Completion date
January 15, 2026
Enrollment
202 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer